Latest Asx Announcements News

Austin Engineering has announced a Board-approved on-market share buy-back of up to 10% of its ordinary shares over the next 12 months, reflecting confidence in its financial strength and growth prospects.

Liberty Group announces a shift to quarterly unfranked distributions, starting with a 7.5 cents per security interim payment for Q3 2025, signaling confidence in its financial stability.

Australian Unity Limited has launched a $120 million equity raising through a non-underwritten entitlement offer and placement, aiming to strengthen its balance sheet and support strategic acquisitions.

Rewardle Holdings has arranged a $2 million revolving standby debt facility with Temorex, secured by its CloudHolter shares, offering fresh working capital and flexible fee payment options.

Metro Finance 2021-1 Trust’s $652 million Class A Notes have been suspended from trading and removed from the ASX Official List following their redemption last November.

Arovella Therapeutics has received a $3.21 million R&D tax incentive refund, bolstering its financial position as it prepares to initiate first-in-human trials for its lead cell therapy, ALA-101.

Buru Energy has extended the closing date for its Share Purchase Plan to October 7, giving eligible shareholders more time to invest at 2 cents per share. The move includes an option to apply for attaching options, signaling confidence from company leadership.

Trading in the Nanuk New World Fund (Currency Hedged) Active ETF has been temporarily halted, with personal trading also paused as investors await further details.

SPDR S&P/ASX 200 ETF (STW) has announced an estimated ordinary dividend of AUD 0.836278 per security for the quarter ending 30 September 2025, with a Dividend Reinvestment Plan available to investors.

Emyria secures a multi-year funding agreement with Medibank to support its Treatment-Resistant Depression program, marking a first for insurer-backed psychotherapy in Australia.

Altamin Limited has launched a $6.46 million accelerated entitlement offer, strongly supported by its largest shareholder, to fund development at its Lazio and Gorno projects. The capital raise aims to advance exploration and maintain operational readiness amid strategic options for Gorno.

BCAL Diagnostics has partnered with US-based ClearNote Health to exclusively distribute innovative blood tests for early detection of pancreatic and ovarian cancers in Australia and New Zealand, starting early 2026.